KURAHealthcare · BiotechnologyThe 16 Wall Street analysts covering Kura Oncology, Inc. hold a median 12-month price target of $28 — +172.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Kura Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (22): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on KURA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +172.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | JP Morgan | Initiates | Overweight | $30 |
| 24 Aug 2026 | Citizens | Reiterates | Market Outperform | — |
| 24 Aug 2026 | Citizens | Reiterates | Market Outperform | $24 |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 13 Aug 2026 | Wedbush | Maintains | Outperform | $36 → $38 |
| 28 July 2026 | Wedbush | Reiterates | Outperform | $36 |
| 28 July 2026 | Wedbush | Reiterates | Outperform | — |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | $24 |
| 15 June 2026 | Citizens | Reiterates | Market Outperform | — |
| 14 Apr 2026 | Lake Street | Initiates | Buy | — |
| 24 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 13 Mar 2026 | UBS | Maintains | Buy | — |
| 6 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 13 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Jan 2026 | Leerink Partners | Maintains | Outperform | — |
| 24 Nov 2025 | Barclays | Maintains | Overweight | — |
| 14 Nov 2025 | UBS | Maintains | Buy | — |
| 14 Nov 2025 | Wedbush | Maintains | Outperform | — |
| 20 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Oct 2025 | JMP Securities | Reiterates | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
KURA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Kura Oncology, Inc. returned −1.7% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 12% of US stocks
Cheaper than 5% of US stocks
Cheaper than 71% of US stocks
Higher than 81% of US stocks
Higher than 70% of US stocks
Higher than 99% of US stocks
Higher than 9% of US stocks
Higher than 99% of US stocks
Higher than 9% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kura Oncology, Inc. has a market value of $912.7M and an enterprise value of $418.2M.
Revenue in the twelve months to 30 June 2026: $77.2M. The latest quarter grew 36.5% year on year.
Net income over the same four quarters: −$296.8M, a −384.3% net margin.
Diluted earnings per share, trailing twelve months: $−3.37.
Free cash flow in the twelve months to 30 June 2026: −$117.4M.
Trailing P/E: −3.2×; forward P/E: −4.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Kura Oncology, Inc. employs 260 people — $297K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kura Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Kura Oncology lacks the combination of two key ingredients it associates with a likely earnings beat ahead of the company’s upcoming Q3 report.
Why it matters — The item highlights expectations around Kura Oncology’s upcoming quarterly earnings report.
Kura Oncology and newly formed affiliate Caspian Therapeutics outlined plans to develop oral menin inhibitor KO-7246 for diabetes. The companies cited preclinical findings of beta-cell expansion, improved glucose control and sustained effects after treatment ended.
Why it matters — The plans add a diabetes development program for Kura’s oral menin inhibitor, based on preclinical data described by the companies.
Seeking Alpha published a transcript discussing Kura Oncology’s KO-7246 data and development strategy for menin inhibitors in diabetes.
Why it matters — The transcript concerns Kura’s reported KO-7246 data and its development strategy in diabetes.
Caspian Therapeutics and Kura Oncology outlined a development strategy for KO-7246, a next-generation oral menin inhibitor for diabetes, citing EASD findings. IND-enabling work is underway to support a Phase 1 proof-of-concept study assessing safety and endogenous insulin production.
Why it matters — The update describes planned clinical development of a Kura-associated menin inhibitor in diabetes, including the intended objectives of a future Phase 1 study.
Caspian Therapeutics and Kura Oncology will host an investor webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT), highlighting Caspian's launch and preclinical data for KO-7246 in diabetes.
Why it matters — KURA watchers may be interested in the planned presentation of preclinical data on the company's KO-7246 program.
The 16 Wall Street analysts covering Kura Oncology, Inc. have a median 12-month price target of $28, with estimates ranging from $15 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Kura Oncology, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kura Oncology, Inc. 75 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Kura Oncology, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +172.9% from the last close, and Ticker Nerd's factor model ranks Kura Oncology, Inc. 75 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kura Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $76 over the next 12 months.
Kura Oncology, Inc. returned -1.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer.
The most recent item we track (Zacks Investment Research, 27 Oct 2026): "Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know". Zacks Investment Research says Kura Oncology lacks the combination of two key ingredients it associates with a likely earnings beat ahead of the company’s upcoming Q3 report.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Kura Oncology’s current portfolio centers on precision oncology programs designed to target specific molecular drivers of disease, with an emphasis on hematologic malignancies and selected solid tumors. Its pipeline includes small-molecule drug candidates such as ziftomenib, tipifarnib, and KO-2806, which are being evaluated in clinical development for genetically defined patient populations. The company’s work combines drug discovery, biomarker-driven research, and clinical testing to support targeted treatment approaches in oncology. Based in San Diego, California, Kura Oncology operates as a focused biotechnology company within the broader cancer therapeutics market, contributing to the development of specialized therapies for patients with high unmet medical need.
CEO Dr. Troy Edward Wilson J.D., Ph.D. · 260 employees · United States · https://www.kuraoncology.com
